# Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

> **NCT01453153** · PHASE1,PHASE2 · COMPLETED · sponsor: **Halozyme Therapeutics** · enrollment: 28 (actual)

## Conditions studied

- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** PEGPH20
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01453153
- **Lead sponsor:** Halozyme Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2014-02
- **Final completion:** 2015-05
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2018-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01453153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01453153, "Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01453153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*